Welcome to our dedicated page for Anika Therapeutics SEC filings (Ticker: ANIK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anika Therapeutics, Inc. (NASDAQ: ANIK) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Anika uses these filings to report its financial results, clinical and regulatory milestones, governance decisions, and equity compensation arrangements as it advances osteoarthritis pain management and regenerative orthopedic solutions based on hyaluronic acid and implant technologies.
Investors can review Form 8-K current reports in which Anika furnishes press releases on quarterly financial results, such as those for the second and third quarters of 2025, and discusses non-GAAP measures like Adjusted EBITDA and adjusted net income from continuing operations. Other 8-K filings describe material events including the filing of the third and final Premarket Approval (PMA) module for the Hyalofast cartilage repair scaffold, topline results from the U.S. pivotal FastTRACK Phase III study, and amendments to the company’s 2017 Omnibus Incentive Plan approved by stockholders.
Through its proxy-related disclosures and meeting results, Anika reports on governance and compensation matters, including director elections, advisory votes on executive compensation, and increases to share reserves under its omnibus incentive plan. Additional filings document inducement equity grants made under a separate inducement plan in accordance with Nasdaq Listing Rule 5635(c)(4), providing detail on stock option terms and vesting conditions for newly hired employees.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of earnings releases, clinical and regulatory updates, plan amendments, and other material events. Users can track new 8-Ks and other SEC forms as they are posted to EDGAR, and use the summaries to focus on the sections most relevant to Anika’s OA pain management and regenerative solutions strategy, capital structure, and corporate governance.
Anika Therapeutics grew its business but remained unprofitable this quarter. Revenue for the three months ended March 31, 2026 rose to $29.6 million, up 13% year over year, driven by stronger OEM sales, especially to J&J MedTech, and higher international OA pain and regenerative product revenue.
Gross margin improved to 64% from 56% as higher volume and lower inventory charges boosted profitability, yet the company posted a net loss of $5.1 million, or $0.37 per share, mainly due to increased stock-based compensation and restructuring-related severance. Adjusted EBITDA turned positive to $4.3 million from $0.1 million, reflecting stronger underlying operations.
Anika is reshaping its cost structure after divesting Arthrosurface and Parcus Medical, focusing on OA Pain Management and Regenerative Solutions. It recorded about $1.6 million of severance and $3.3 million of stock-based expense tied to a CEO transition. Cash and equivalents were $41.0 million with no debt, after funding $8.7 million of share repurchases under a $40 million program.
Anika Therapeutics Inc ownership filing: Vanguard Capital Management reports beneficial ownership of 695,697 shares of Common Stock, representing 5.19% of the class. The filing shows sole voting power of 89,920 shares and sole dispositive power for 695,697 shares.
The filing is submitted on behalf of Vanguard Capital Management and affiliated business divisions; the signature is by Ashley Grim, Head of Global Fund Administration.
Anika Therapeutics reported first quarter 2026 revenue of $29.6 million, up 13% from $26.2 million a year earlier, driven by OEM Channel revenue of $17.0 million, up 14%, and Commercial Channel revenue of $12.6 million, up 12%.
Gross margin improved to 64.2% from 56.1% as gross profit rose to $19.0 million. Operating expenses increased to $24.5 million, including $4.9 million of one-time severance costs. The company recorded a GAAP loss from continuing operations of $5.1 million, or $0.37 per diluted share.
Non-GAAP results showed adjusted net income from continuing operations of $3.8 million, or $0.27 per diluted share, and adjusted EBITDA of $4.3 million versus $0.1 million a year earlier. Cash and cash equivalents were $41.0 million as of March 31, 2026.
The company reaffirmed its 2026 guidance, with total revenue expected between $114 million and $122.5 million and adjusted EBITDA margin between 5% and 10%. Anika also completed its previously announced $15 million 10b5-1 share repurchase at an average price of $10.76 per share. Separately, directors William Jellison and Glenn Larsen will step down at the 2026 annual meeting, and the board will be reduced from nine to seven members; their resignations are not due to any disagreement with the company.
Anika Therapeutics, Inc. is asking stockholders to vote at its June 18, 2026 virtual annual meeting on five items: electing three Class III directors, ratifying Deloitte & Touche LLP as 2026 auditor, an advisory say‑on‑pay vote, and amendments to its 2017 Omnibus Incentive Plan and 2021 Employee Stock Purchase Plan.
The company reports 2025 growth led by its Commercial Channel, with Commercial revenue up 15% year over year and 22% in the fourth quarter, driven by international OA Pain Management and the Integrity Implant System. Hyalofast advanced toward a future U.S. launch following filing of the final PMA module and FDA feedback.
The board seeks to add 475,000 shares to the 2017 Omnibus Incentive Plan, bringing 1,269,928 shares reserved (8.8% of fully diluted common stock) and doubling the ESPP reserve from 200,000 to 400,000 shares. Governance highlights include a majority voting policy for uncontested director elections, fully independent key committees, and separation of Executive Chair, Lead Independent Director, and CEO roles.
Anika Therapeutics Inc Schedule 13G/A amendment shows The Vanguard Group reporting 0 shares beneficially owned and 0% of the common stock following an internal realignment.
The filing explains that certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538; Vanguard states it no longer is deemed to beneficially own the securities held by those subsidiaries.
Anika Therapeutics SVP, CAO & Treasurer Ian McLeod received new equity awards. On March 19, 2026, he was granted 13,097 Restricted Stock Units and a separate 11,194 RSU award, each representing a contingent right to one share of common stock or cash on vesting. He also received 17,663 Premium Priced Stock Appreciation Rights with a $15.60 exercise price, vesting in three annual installments starting March 19, 2027, and expiring on March 19, 2036.
Anika Therapeutics EVP and General Counsel David Colleran reported equity award vesting and related tax withholding, not open-market trading. On March 14, 2026 and March 15, 2026, he exercised a total of 15,837 restricted stock units into the same number of common shares at $0.00 per share.
He also received a grant or award of 4,694 common shares. To cover tax obligations on these RSU and PSU vestings, 4,168 and 1,893 shares of common stock were withheld at $14.20 per share. Following these transactions, Colleran directly holds 67,570 shares of Anika Therapeutics common stock, with additional RSU awards continuing to vest over time as indicated in the footnotes.
Anika Therapeutics President and CEO Stephen D. Griffin reported equity compensation activity tied to vesting restricted stock units. On March 14, 2026, he exercised 12,824 restricted stock units, receiving 12,824 shares of common stock at a stated exercise price of $0.00 per share.
On the same date, he also acquired 6,412 shares of common stock as a grant or award, and 5,944 shares were withheld by the company at $14.20 per share to cover tax obligations related to vested RSUs and PSUs. Following these transactions, Griffin directly owns 23,963 shares of Anika Therapeutics common stock.
Anika Therapeutics director Cheryl R. Blanchard reported compensation-related stock activity involving restricted stock units (RSUs) and performance-based RSUs (PSUs). On March 14, 2026, 24,519 RSUs and 24,519 PSUs vested and were converted into common shares, and she also received a grant of 24,520 common shares.
On March 15, 2026, an additional 25,131 RSUs vested and were converted into 25,131 common shares. To cover related tax withholding obligations, the company retained 14,728 shares on March 14 and 12,104 shares on March 15 at a price of $14.20 per share, rather than selling shares in the open market.
Following these transactions, Blanchard directly holds 258,788 common shares and indirectly holds 11,742 shares through a revocable trust of which she is the sole trustee and a beneficiary. The transactions reflect equity awards vesting and associated tax withholding, not open-market purchases or sales.